http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 21 Aug 2026 19:57:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Zura+Bio+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26962770.html <p> HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on August 20, 2026, the Company granted inducement awards consisting of options to purchase up to 587,000 Class A Ordinary Shares (the “Options”) to thirteen newly hired employees. These awards were approved by the Compensation Committee of the Company’s Board of Directors and granted outside the Company’s 2023 Equity Incentive Plan, as amended (the “Plan”), as inducements material http://www.streetinsider.com/Press+Releases/Zura+Bio+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26962770.html Fri, 21 Aug 2026 19:57:00 -0400 O.50982924 ZURA http://www.streetinsider.com/Press+Releases/Zura+Bio+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26962770.html <p> HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on August 20, 2026, the Company granted inducement awards consisting of options to purchase up to 587,000 Class A Ordinary Shares (the “Options”) to thirteen newly hired employees. These awards were approved by the Compensation Committee of the Company’s Board of Directors and granted outside the Company’s 2023 Equity Incentive Plan, as amended (the “Plan”), as inducements material http://www.streetinsider.com/Press+Releases/Zura+Bio+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26962770.html Fri, 21 Aug 2026 19:57:00 -0400 O.50982924 ZURA http://www.streetinsider.com/Business+Wire/Zura+Bio+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26962770.html <p> HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on August 20, 2026, the Company granted inducement awards consisting of options to purchase up to 587,000 Class A Ordinary Shares (the “Options”) to thirteen newly hired employees. These awards were approved by the Compensation Committee of the Company’s Board of Directors and granted outside the Company’s 2023 Equity Incentive Plan, as amended (the “Plan”), as inducements material http://www.streetinsider.com/Business+Wire/Zura+Bio+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26962770.html Fri, 21 Aug 2026 19:57:00 -0400 O.50982924 ZURA http://www.streetinsider.com/Business+Wire/Zura+Bio+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26962770.html <p> HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on August 20, 2026, the Company granted inducement awards consisting of options to purchase up to 587,000 Class A Ordinary Shares (the “Options”) to thirteen newly hired employees. These awards were approved by the Compensation Committee of the Company’s Board of Directors and granted outside the Company’s 2023 Equity Incentive Plan, as amended (the “Plan”), as inducements material http://www.streetinsider.com/Business+Wire/Zura+Bio+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26962770.html Fri, 21 Aug 2026 19:57:00 -0400 O.50982924 ZURA http://www.streetinsider.com/Analyst+PT+Change/Zura+Bio+Ltd.+%28ZURA%29+PT+Raised+to+%2420+at+Guggenheim/26908623.html (Updated - August 12, 2026 6:57 AM EDT) <p>Guggenheim analyst Yatin Suneja raised the price target on Zura Bio Ltd. (NASDAQ: ZURA) to $20.00 (from $15.00) while maintaining a Buy rating.</p><p>The analyst commented: "This morning, ZURA reported 2Q26 earnings alongside notable corporate updates, most notably disclosing a 3rd indication for its first-in-class BAFFxIL-17A bispecific, tibulizumab: polymyalgia rheumatica (PMR). Given robust clinical evidence of IL-17 (Cosentyx) and B-cell–targeted (Rituximab) therapies delivering glucocorticoid sparing benefit in PMR, we believe tibulizumab's dual anti-BAFF x anti-IL-17A mechanism could offer unique, orthogonal benefit in this underpenetrated, high unmet-need indication. ZURA plans to initiate a placebo-controlled Phase http://www.streetinsider.com/Analyst+PT+Change/Zura+Bio+Ltd.+%28ZURA%29+PT+Raised+to+%2420+at+Guggenheim/26908623.html Wed, 12 Aug 2026 06:57:27 -0400 ZURA http://www.streetinsider.com/Analyst+Comments/Zura+Bio+Ltd.+%28ZURA%29+PT+Raised+to+%2420+at+Guggenheim/26908623.html (Updated - August 12, 2026 6:57 AM EDT) <p>Guggenheim analyst Yatin Suneja raised the price target on Zura Bio Ltd. (NASDAQ: ZURA) to $20.00 (from $15.00) while maintaining a Buy rating.</p><p>The analyst commented: "This morning, ZURA reported 2Q26 earnings alongside notable corporate updates, most notably disclosing a 3rd indication for its first-in-class BAFFxIL-17A bispecific, tibulizumab: polymyalgia rheumatica (PMR). Given robust clinical evidence of IL-17 (Cosentyx) and B-cell–targeted (Rituximab) therapies delivering glucocorticoid sparing benefit in PMR, we believe tibulizumab's dual anti-BAFF x anti-IL-17A mechanism could offer unique, orthogonal benefit in this underpenetrated, high unmet-need indication. ZURA plans to initiate a placebo-controlled Phase http://www.streetinsider.com/Analyst+Comments/Zura+Bio+Ltd.+%28ZURA%29+PT+Raised+to+%2420+at+Guggenheim/26908623.html Wed, 12 Aug 2026 06:57:27 -0400 ZURA http://www.streetinsider.com/Earnings/Zura+Bio+%28ZURA%29+Misses+Q2+EPS+by+2c/26901775.html <p>Zura Bio (NASDAQ: ZURA) reported Q2 EPS of ($0.21), $0.02 worse than the analyst estimate of ($0.19).</p><p>For earnings history and earnings-related data on Zura Bio (ZURA) <a href="http://www.streetinsider.com/ec_earnings.php?q=ZURA">click here</a>.</p> http://www.streetinsider.com/Earnings/Zura+Bio+%28ZURA%29+Misses+Q2+EPS+by+2c/26901775.html Tue, 11 Aug 2026 08:00:53 -0400 ZURA http://www.streetinsider.com/Press+Releases/Zura+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates/26901413.html <ul class="bwlistdisc"> <li> <i>TibuSHIELD enrollment complete, exceeding initial enrollment target with 247 participants randomized in HS; topline data expected Q4 2026</i> </li> <li> <i>TibuSURE enrollment complete, exceeding initial enrollment target with 91 participants randomized in SSc; topline data expected H1 2027</i> </li> <li> <i>Zura plans to initiate a Phase 2 study for tibulizumab in polymyalgia rheumatica (PMR) by year-end 2026</i> </li> <li> <i>Cash and cash equivalents of $205.1 million as of June 30, 2026, which is expected to fund planned operations through at least the end of 2028</i> </li> </ul> <p> HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve http://www.streetinsider.com/Press+Releases/Zura+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates/26901413.html Tue, 11 Aug 2026 07:30:00 -0400 A.06822034 O.20026344 O.50982924 ZURA http://www.streetinsider.com/Press+Releases/Zura+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates/26901413.html <ul class="bwlistdisc"> <li> <i>TibuSHIELD enrollment complete, exceeding initial enrollment target with 247 participants randomized in HS; topline data expected Q4 2026</i> </li> <li> <i>TibuSURE enrollment complete, exceeding initial enrollment target with 91 participants randomized in SSc; topline data expected H1 2027</i> </li> <li> <i>Zura plans to initiate a Phase 2 study for tibulizumab in polymyalgia rheumatica (PMR) by year-end 2026</i> </li> <li> <i>Cash and cash equivalents of $205.1 million as of June 30, 2026, which is expected to fund planned operations through at least the end of 2028</i> </li> </ul> <p> HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve http://www.streetinsider.com/Press+Releases/Zura+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates/26901413.html Tue, 11 Aug 2026 07:30:00 -0400 A.06822034 O.20026344 O.50982924 ZURA http://www.streetinsider.com/Press+Releases/Zura+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates/26901413.html <ul class="bwlistdisc"> <li> <i>TibuSHIELD enrollment complete, exceeding initial enrollment target with 247 participants randomized in HS; topline data expected Q4 2026</i> </li> <li> <i>TibuSURE enrollment complete, exceeding initial enrollment target with 91 participants randomized in SSc; topline data expected H1 2027</i> </li> <li> <i>Zura plans to initiate a Phase 2 study for tibulizumab in polymyalgia rheumatica (PMR) by year-end 2026</i> </li> <li> <i>Cash and cash equivalents of $205.1 million as of June 30, 2026, which is expected to fund planned operations through at least the end of 2028</i> </li> </ul> <p> HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve http://www.streetinsider.com/Press+Releases/Zura+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates/26901413.html Tue, 11 Aug 2026 07:30:00 -0400 A.06822034 O.20026344 O.50982924 ZURA http://www.streetinsider.com/Press+Releases/Zura+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates/26901413.html <ul class="bwlistdisc"> <li> <i>TibuSHIELD enrollment complete, exceeding initial enrollment target with 247 participants randomized in HS; topline data expected Q4 2026</i> </li> <li> <i>TibuSURE enrollment complete, exceeding initial enrollment target with 91 participants randomized in SSc; topline data expected H1 2027</i> </li> <li> <i>Zura plans to initiate a Phase 2 study for tibulizumab in polymyalgia rheumatica (PMR) by year-end 2026</i> </li> <li> <i>Cash and cash equivalents of $205.1 million as of June 30, 2026, which is expected to fund planned operations through at least the end of 2028</i> </li> </ul> <p> HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve http://www.streetinsider.com/Press+Releases/Zura+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates/26901413.html Tue, 11 Aug 2026 07:30:00 -0400 A.06822034 O.20026344 O.50982924 ZURA http://www.streetinsider.com/Business+Wire/Zura+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates/26901413.html <ul class="bwlistdisc"> <li> <i>TibuSHIELD enrollment complete, exceeding initial enrollment target with 247 participants randomized in HS; topline data expected Q4 2026</i> </li> <li> <i>TibuSURE enrollment complete, exceeding initial enrollment target with 91 participants randomized in SSc; topline data expected H1 2027</i> </li> <li> <i>Zura plans to initiate a Phase 2 study for tibulizumab in polymyalgia rheumatica (PMR) by year-end 2026</i> </li> <li> <i>Cash and cash equivalents of $205.1 million as of June 30, 2026, which is expected to fund planned operations through at least the end of 2028</i> </li> </ul> <p> HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve http://www.streetinsider.com/Business+Wire/Zura+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates/26901413.html Tue, 11 Aug 2026 07:30:00 -0400 A.06822034 O.20026344 O.50982924 ZURA http://www.streetinsider.com/Business+Wire/Zura+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates/26901413.html <ul class="bwlistdisc"> <li> <i>TibuSHIELD enrollment complete, exceeding initial enrollment target with 247 participants randomized in HS; topline data expected Q4 2026</i> </li> <li> <i>TibuSURE enrollment complete, exceeding initial enrollment target with 91 participants randomized in SSc; topline data expected H1 2027</i> </li> <li> <i>Zura plans to initiate a Phase 2 study for tibulizumab in polymyalgia rheumatica (PMR) by year-end 2026</i> </li> <li> <i>Cash and cash equivalents of $205.1 million as of June 30, 2026, which is expected to fund planned operations through at least the end of 2028</i> </li> </ul> <p> HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve http://www.streetinsider.com/Business+Wire/Zura+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates/26901413.html Tue, 11 Aug 2026 07:30:00 -0400 A.06822034 O.20026344 O.50982924 ZURA http://www.streetinsider.com/Business+Wire/Zura+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates/26901413.html <ul class="bwlistdisc"> <li> <i>TibuSHIELD enrollment complete, exceeding initial enrollment target with 247 participants randomized in HS; topline data expected Q4 2026</i> </li> <li> <i>TibuSURE enrollment complete, exceeding initial enrollment target with 91 participants randomized in SSc; topline data expected H1 2027</i> </li> <li> <i>Zura plans to initiate a Phase 2 study for tibulizumab in polymyalgia rheumatica (PMR) by year-end 2026</i> </li> <li> <i>Cash and cash equivalents of $205.1 million as of June 30, 2026, which is expected to fund planned operations through at least the end of 2028</i> </li> </ul> <p> HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve http://www.streetinsider.com/Business+Wire/Zura+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates/26901413.html Tue, 11 Aug 2026 07:30:00 -0400 A.06822034 O.20026344 O.50982924 ZURA http://www.streetinsider.com/Business+Wire/Zura+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates/26901413.html <ul class="bwlistdisc"> <li> <i>TibuSHIELD enrollment complete, exceeding initial enrollment target with 247 participants randomized in HS; topline data expected Q4 2026</i> </li> <li> <i>TibuSURE enrollment complete, exceeding initial enrollment target with 91 participants randomized in SSc; topline data expected H1 2027</i> </li> <li> <i>Zura plans to initiate a Phase 2 study for tibulizumab in polymyalgia rheumatica (PMR) by year-end 2026</i> </li> <li> <i>Cash and cash equivalents of $205.1 million as of June 30, 2026, which is expected to fund planned operations through at least the end of 2028</i> </li> </ul> <p> HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve http://www.streetinsider.com/Business+Wire/Zura+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Updates/26901413.html Tue, 11 Aug 2026 07:30:00 -0400 A.06822034 O.20026344 O.50982924 ZURA http://www.streetinsider.com/New+Coverage/William+Blair+Starts+Zura+Bio+Ltd.+%28ZURA%29+at+Outperform/26743458.html <p>William Blair analyst Matt Phipps initiates coverage on Zura Bio Ltd. (NASDAQ: ZURA) with a Outperform rating.</p><p>The analyst comments "We are initiating coverage of Zura Bio based on the potential of the dual mechanism of action with the bispecific tibulizumab to drive differentiated efficacy in two ongoing Phase II studies in hidradenitis suppurativa (HS) and systemic sclerosis (SSc). As outlined in this report, we believe there is significant translational data to support the role of both B cells and T cells in driving immunopathogenesis and inflammation in many autoimmune diseases, particularly HS and SSc. By inhibiting both BAFF and IL-17, http://www.streetinsider.com/New+Coverage/William+Blair+Starts+Zura+Bio+Ltd.+%28ZURA%29+at+Outperform/26743458.html Wed, 08 Jul 2026 04:51:23 -0400 ZURA http://www.streetinsider.com/Analyst+Comments/William+Blair+Starts+Zura+Bio+Ltd.+%28ZURA%29+at+Outperform/26743458.html <p>William Blair analyst Matt Phipps initiates coverage on Zura Bio Ltd. (NASDAQ: ZURA) with a Outperform rating.</p><p>The analyst comments "We are initiating coverage of Zura Bio based on the potential of the dual mechanism of action with the bispecific tibulizumab to drive differentiated efficacy in two ongoing Phase II studies in hidradenitis suppurativa (HS) and systemic sclerosis (SSc). As outlined in this report, we believe there is significant translational data to support the role of both B cells and T cells in driving immunopathogenesis and inflammation in many autoimmune diseases, particularly HS and SSc. By inhibiting both BAFF and IL-17, http://www.streetinsider.com/Analyst+Comments/William+Blair+Starts+Zura+Bio+Ltd.+%28ZURA%29+at+Outperform/26743458.html Wed, 08 Jul 2026 04:51:23 -0400 ZURA http://www.streetinsider.com/FDA/Zura+Bio+exceeds+enrollment+targets+in+two+Phase+2+drug+trials/26702106.html <p>Zura Bio Limited (Nasdaq: ZURA) announced that its Phase 2 TibuSHIELD trial of tibulizumab in adults with hidradenitis suppurativa (HS) has completed enrollment with 247 participants, exceeding its original target. The company also said its TibuSURE trial in adults with early diffuse cutaneous systemic sclerosis (SSc) has surpassed its 80-participant enrollment target and remains on track to complete enrollment in early July.</p> <p>Topline data from TibuSHIELD are expected in the fourth quarter of 2026, while topline data from TibuSURE are expected in the first half of 2027.</p> <p>Tibulizumab is a bispecific antibody targeting both IL-17 and BAFF pathways. Zura said it plans http://www.streetinsider.com/FDA/Zura+Bio+exceeds+enrollment+targets+in+two+Phase+2+drug+trials/26702106.html Mon, 29 Jun 2026 07:30:42 -0400 O.50982924 ZURA http://www.streetinsider.com/FDA/Zura+Bio+exceeds+enrollment+targets+in+two+Phase+2+drug+trials/26702106.html <p>Zura Bio Limited (Nasdaq: ZURA) announced that its Phase 2 TibuSHIELD trial of tibulizumab in adults with hidradenitis suppurativa (HS) has completed enrollment with 247 participants, exceeding its original target. The company also said its TibuSURE trial in adults with early diffuse cutaneous systemic sclerosis (SSc) has surpassed its 80-participant enrollment target and remains on track to complete enrollment in early July.</p> <p>Topline data from TibuSHIELD are expected in the fourth quarter of 2026, while topline data from TibuSURE are expected in the first half of 2027.</p> <p>Tibulizumab is a bispecific antibody targeting both IL-17 and BAFF pathways. Zura said it plans http://www.streetinsider.com/FDA/Zura+Bio+exceeds+enrollment+targets+in+two+Phase+2+drug+trials/26702106.html Mon, 29 Jun 2026 07:30:42 -0400 O.50982924 ZURA http://www.streetinsider.com/Press+Releases/Zura+Bio+Exceeds+Enrollment+Target+in+Both+Hidradenitis+Suppurativa+%28HS%29+%26amp%3B+Systemic+Sclerosis+%28SSc%29+Phase+2+Studies+and+Expands+Tibulizumab+Program/26702091.html <ul class="bwlistdisc"> <li> <i>Tibulizumab is the first and only bispecific antibody targeting both BAFF and IL-17 in clinical development</i> </li> <li> <i>TibuSHIELD has completed enrollment, exceeding enrollment target with 247 participants randomized in HS; topline data expected Q4 2026</i> </li> <li> <i>TibuSURE has exceeded the 80 participant enrollment target in SSc and remains on track to complete enrollment in early July; topline data expected H1 2027</i> </li> <li> <i>Zura plans to initiate a Phase 2 study for tibulizumab in a third immune-mediated indication by year end 2026</i> </li> </ul> <p> HENDERSON, Nev.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fzurabio.com%2F&amp;esheet=54561049&amp;newsitemid=20260629189605&amp;lan=en-US&amp;anchor=Zura+Bio+Limited&amp;index=1&amp;md5=b00db38a460943f5374b3727cb445134" shape="rect">Zura Bio Limited</a> (Nasdaq: ZURA) (“Zura”), a clinical stage biotechnology company developing novel and differentiated http://www.streetinsider.com/Press+Releases/Zura+Bio+Exceeds+Enrollment+Target+in+Both+Hidradenitis+Suppurativa+%28HS%29+%26amp%3B+Systemic+Sclerosis+%28SSc%29+Phase+2+Studies+and+Expands+Tibulizumab+Program/26702091.html Mon, 29 Jun 2026 07:30:00 -0400 O.50982924 ZURA http://www.streetinsider.com/Press+Releases/Zura+Bio+Exceeds+Enrollment+Target+in+Both+Hidradenitis+Suppurativa+%28HS%29+%26amp%3B+Systemic+Sclerosis+%28SSc%29+Phase+2+Studies+and+Expands+Tibulizumab+Program/26702091.html <ul class="bwlistdisc"> <li> <i>Tibulizumab is the first and only bispecific antibody targeting both BAFF and IL-17 in clinical development</i> </li> <li> <i>TibuSHIELD has completed enrollment, exceeding enrollment target with 247 participants randomized in HS; topline data expected Q4 2026</i> </li> <li> <i>TibuSURE has exceeded the 80 participant enrollment target in SSc and remains on track to complete enrollment in early July; topline data expected H1 2027</i> </li> <li> <i>Zura plans to initiate a Phase 2 study for tibulizumab in a third immune-mediated indication by year end 2026</i> </li> </ul> <p> HENDERSON, Nev.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fzurabio.com%2F&amp;esheet=54561049&amp;newsitemid=20260629189605&amp;lan=en-US&amp;anchor=Zura+Bio+Limited&amp;index=1&amp;md5=b00db38a460943f5374b3727cb445134" shape="rect">Zura Bio Limited</a> (Nasdaq: ZURA) (“Zura”), a clinical stage biotechnology company developing novel and differentiated http://www.streetinsider.com/Press+Releases/Zura+Bio+Exceeds+Enrollment+Target+in+Both+Hidradenitis+Suppurativa+%28HS%29+%26amp%3B+Systemic+Sclerosis+%28SSc%29+Phase+2+Studies+and+Expands+Tibulizumab+Program/26702091.html Mon, 29 Jun 2026 07:30:00 -0400 O.50982924 ZURA http://www.streetinsider.com/Business+Wire/Zura+Bio+Exceeds+Enrollment+Target+in+Both+Hidradenitis+Suppurativa+%28HS%29+%26amp%3B+Systemic+Sclerosis+%28SSc%29+Phase+2+Studies+and+Expands+Tibulizumab+Program/26702091.html <ul class="bwlistdisc"> <li> <i>Tibulizumab is the first and only bispecific antibody targeting both BAFF and IL-17 in clinical development</i> </li> <li> <i>TibuSHIELD has completed enrollment, exceeding enrollment target with 247 participants randomized in HS; topline data expected Q4 2026</i> </li> <li> <i>TibuSURE has exceeded the 80 participant enrollment target in SSc and remains on track to complete enrollment in early July; topline data expected H1 2027</i> </li> <li> <i>Zura plans to initiate a Phase 2 study for tibulizumab in a third immune-mediated indication by year end 2026</i> </li> </ul> <p> HENDERSON, Nev.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fzurabio.com%2F&amp;esheet=54561049&amp;newsitemid=20260629189605&amp;lan=en-US&amp;anchor=Zura+Bio+Limited&amp;index=1&amp;md5=b00db38a460943f5374b3727cb445134" shape="rect">Zura Bio Limited</a> (Nasdaq: ZURA) (“Zura”), a clinical stage biotechnology company developing novel and differentiated http://www.streetinsider.com/Business+Wire/Zura+Bio+Exceeds+Enrollment+Target+in+Both+Hidradenitis+Suppurativa+%28HS%29+%26amp%3B+Systemic+Sclerosis+%28SSc%29+Phase+2+Studies+and+Expands+Tibulizumab+Program/26702091.html Mon, 29 Jun 2026 07:30:00 -0400 O.50982924 ZURA http://www.streetinsider.com/Business+Wire/Zura+Bio+Exceeds+Enrollment+Target+in+Both+Hidradenitis+Suppurativa+%28HS%29+%26amp%3B+Systemic+Sclerosis+%28SSc%29+Phase+2+Studies+and+Expands+Tibulizumab+Program/26702091.html <ul class="bwlistdisc"> <li> <i>Tibulizumab is the first and only bispecific antibody targeting both BAFF and IL-17 in clinical development</i> </li> <li> <i>TibuSHIELD has completed enrollment, exceeding enrollment target with 247 participants randomized in HS; topline data expected Q4 2026</i> </li> <li> <i>TibuSURE has exceeded the 80 participant enrollment target in SSc and remains on track to complete enrollment in early July; topline data expected H1 2027</i> </li> <li> <i>Zura plans to initiate a Phase 2 study for tibulizumab in a third immune-mediated indication by year end 2026</i> </li> </ul> <p> HENDERSON, Nev.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fzurabio.com%2F&amp;esheet=54561049&amp;newsitemid=20260629189605&amp;lan=en-US&amp;anchor=Zura+Bio+Limited&amp;index=1&amp;md5=b00db38a460943f5374b3727cb445134" shape="rect">Zura Bio Limited</a> (Nasdaq: ZURA) (“Zura”), a clinical stage biotechnology company developing novel and differentiated http://www.streetinsider.com/Business+Wire/Zura+Bio+Exceeds+Enrollment+Target+in+Both+Hidradenitis+Suppurativa+%28HS%29+%26amp%3B+Systemic+Sclerosis+%28SSc%29+Phase+2+Studies+and+Expands+Tibulizumab+Program/26702091.html Mon, 29 Jun 2026 07:30:00 -0400 O.50982924 ZURA http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Zura+Bio+Ltd++++++++++++++For%3A+Apr+17++Filed+by%3A+Mathew+Marlyn+Teresa/26673903.html si-local-file:///var/storage/secattach/20260622/26673903.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Zura+Bio+Ltd++++++++++++++For%3A+Apr+17++Filed+by%3A+Mathew+Marlyn+Teresa/26673903.html Mon, 22 Jun 2026 16:55:00 -0400 O.50982924 ZURA http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Zura+Bio+Ltd++++++++++++++For%3A+Apr+17++Filed+by%3A+Mathew+Marlyn+Teresa/26673903.html si-local-file:///var/storage/secattach/20260622/26673903.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Zura+Bio+Ltd++++++++++++++For%3A+Apr+17++Filed+by%3A+Mathew+Marlyn+Teresa/26673903.html Mon, 22 Jun 2026 16:55:00 -0400 O.50982924 ZURA